Latest Angina Companies Update
Nov 2023: Astellas Pharma and the University of Tsukuba in Japan have inked a letter of confirmation confirming their strategic partnership to speed up innovative drug discovery research and development, as well as the digitalization of the drug discovery research field and the growth of the life science ecosystem in Tsukuba and Kashiwa-no-ha. This agreement calls for the two parties to share information and discuss topics such as promoting drug discovery and other research, creating new startups via industry-academia collaboration, using state-of-the-art research equipment, data related to drug discovery, and research seeds that are mutually owned, holding talks and seminars to advance and develop joint studies previously carried out by the two parties, and promoting drug discovery research and the creation of new startups through exchange and communication with third-party venture company innovators in residence at SakuLabâ„¢-Tsukuba.
Nov 2023: A high-tech facility was unveiled by Bayer as part of a billion euros worth of worldwide investment effort. The cutting-edge area speeds up medication manufacture using a robot-controlled aseptic filling line. Located in Berlin, Germany, the global pharmaceutical hub of Bayer, the plant is a critical production location currently developing into a global "Center of Excellence for Parenterals." Innovative platform technology is used in Bayer's state-of-the-art production plant to produce various parenteral goods. Thanks to the digitalized process, pharmaceuticals are produced quickly and safely, and automated robot-based filling equipment increases productivity.List of Angina Key companies in the market
- Anthera (U.S.)
- Taxus Cardium (U.S.)
- Astellas Pharma (Japan)
- Sanofi (France)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Torrent Pharmaceuticals Limited (India)
- Huya Bioscience International (U.S.)
- Viromed Co. Ltd. (South Korea)
- Baxter (U.S.)